Mariaelena Pierobon

Sep 25, 2024 | nature.com | Mariaelena Pierobon

AbstractMutations of the PIK3CA/AKT/mTOR axis are common events in metastatic breast cancers (MBCs). This study was designed to evaluate the extent to which genetic alterations of the PIK3CA/AKT/mTOR can predict protein activation of this signalling axis in MBCs.Molecular profiles were generated by CLIA-certified laboratories from a real-world evidence cohort of 171 MBC patients. Genetic alterations of the PIK3CA pathway were measured using next-generation sequencing.

May 30, 2024 | nature.com | Andrew Waters |Justine C. Rutter |Shannon McCall |Mariaelena Pierobon |J. Joshua Smith |Channing J. Der

AbstractAcquired resistance remains a major challenge for therapies targeting oncogene activated pathways. KRAS is the most frequently mutated oncogene in human cancers, yet strategies targeting its downstream signaling kinases have failed to produce durable treatment responses.

May 5, 2024 | nature.com | Nicholas W Bateman |Tamara Abulez |Dale W. Garsed |Pang-ning Teng |Clifton L. Dalgard |Mariaelena Pierobon | +5 more

Correction to: npj Precision Oncology https://doi.org/10.1038/s41698-024-00519-8, published online 13 March 2024In the original version of this article, the wrong file was inadvertently supplied for Supplementary Data 15. The original article has been corrected.

Mar 12, 2024 | nature.com | Nicholas W Bateman |Tamara Abulez |Dale W. Garsed |Pang-ning Teng |Clifton L. Dalgard |Mariaelena Pierobon | +5 more

AbstractWe performed a deep proteogenomic analysis of bulk tumor and laser microdissection enriched tumor cell populations from high-grade serous ovarian cancer (HGSOC) tissue specimens spanning a broad spectrum of purity.